Table 1.
Demographics and clinical background of the study population.
| Control Group (n = 19) | CRSsNP Group (n = 13) | CRSwNP Group (n = 31) | |
|---|---|---|---|
| Males/Females | 9/10 | 8/5 | 14/17 |
| Age | 46.4 (19.4) | 50 (18.6) | 56.2 (13.2) |
| Allergic rhinitis | 10 (52.6%) | 10 (76.9%) | 20 (64.5%) |
| BMI, kg/mm2 | 22 (2.5) | 22.5 (2.8) | 22.6 (3.3) |
| Bronchial asthma | 1 (5.2%) | 3 (23%) | 14 (45.1%) ** |
| Blood eosinophils, % | 2.9 (2.5) | 4.1 (2.9) | 6.4 (4.0) †† |
| FeNO, ppb | 21.33 (19.16) | 16.54 (12.65) | 32.13 (27.86) † |
| Tissue eosinophils, cells/HPF | 15.6 (26.2) | 30.1 (44.8) | 133.8 (111.3) *** |
| CT score | - | 6.5 (4.3) | 15.9 (6.5) *** |
| LOX-1 serum levels, pg/mL | 417 (264.7) | 473.8 (329.5) | 585.7 (390.2) |
Data are the mean ± standard deviation (SD) or the number with percentages in parentheses. ** p < 0.01, *** p < 0.001 vs. the other groups. † p < 0.05 vs. the CRSsNP group. †† p < 0.01 vs. the control group. BMI: body-mass index, CRSsNP: chronic rhinosinusitis without nasal polyps, CRSwNP: chronic rhinosinusitis with nasal polyps, FeNO: fractional exhaled nitric oxide, HPF: high power field (x400).